-
公开(公告)号:EP3440097B1
公开(公告)日:2024-10-23
申请号:EP17718218.5
申请日:2017-04-03
-
公开(公告)号:EP4355350A1
公开(公告)日:2024-04-24
申请号:EP22820994.6
申请日:2022-06-08
-
公开(公告)号:EP3233888B1
公开(公告)日:2023-02-22
申请号:EP15820747.2
申请日:2015-12-15
-
公开(公告)号:EP2813512B1
公开(公告)日:2021-03-31
申请号:EP12861199.3
申请日:2012-12-28
发明人: KARIYUKI, Shiori , IIDA, Takeo , KOJIMA, Miki , TAKEYAMA, Ryuichi , TANADA, Mikimasa , KOJIMA, Tetsuo , IIKURA, Hitoshi , MATSUO, Atsushi , SHIRAISHI, Takuya , EMURA, Takashi , NAKANO, Kazuhiko , TAKANO, Koji , ASOU, Kousuke , TORIZAWA, Takuya , TAKANO, Ryusuke , HISADA, Nozomi , MURAO, Naoaki , OHTA, Atsushi , KIMURA, Kaori , YAMAGISHI, Yusuke , KATO, Tatsuya
-
公开(公告)号:EP3778623A1
公开(公告)日:2021-02-17
申请号:EP20185463.5
申请日:2014-03-14
摘要: The present invention relates to an ionic complex comprising a cationic polypeptide and an anionic excipient selected from: a PEG-carboxylic acid; a fatty acid having 10 or more carbon atoms; an anionic phospholipid; and a combination thereof. The invention also relates to a pharmaceutical composition comprising the ionic complex of the invention and a pharmaceutically acceptable carrier. The cationic polypeptide of the ionic complex has pharmacological activity and the complex can provide a more desirable pharmacokinetic profile for the cationic polypeptide of the complex as compared to the cationic polypeptide alone following administration. As such, the invention also relates to the use of the ionic complex and pharmaceutical composition comprising same to treat a subject suffering from a disease or disorder that is responsive to the cationic polypeptide of the ionic complex.
-
公开(公告)号:EP3059244B1
公开(公告)日:2020-08-26
申请号:EP14853408.4
申请日:2014-10-15
发明人: SUGA, Hiroaki , ITO, Kenichiro
-
公开(公告)号:EP3450449A2
公开(公告)日:2019-03-06
申请号:EP18183527.3
申请日:2014-03-14
摘要: The present invention relates to polypeptide compounds that are modulators (e.g., agonists and antagonists) of the melanocortin-4 receptor (MC4R) and pharmaceutical compositions comprising same. The compounds described herein are polypeptide of the following structural Formula (I): or a pharmaceutically acceptable salt thereof. Values and preferred values of the variables in structural Formula (I) are described herein.
-
公开(公告)号:EP3122764B1
公开(公告)日:2019-01-16
申请号:EP15720489.2
申请日:2015-03-25
申请人: LanthioPep B.V.
发明人: RINK, Rick
-
公开(公告)号:EP3337494A1
公开(公告)日:2018-06-27
申请号:EP16757590.1
申请日:2016-08-16
发明人: SCHIFFER, Guido , FÄLKER, Stefan , DAUBE, Gert , FRAATZ, Kristine , WIEHL, Wolfgang , KÖBBERLING, Johannes
摘要: The present invention relates to lysobactin for use in the treatment of bovine mastitis.
-
公开(公告)号:EP3253775A1
公开(公告)日:2017-12-13
申请号:EP16710344.9
申请日:2016-02-02
发明人: MILLER, Michael Matthew , ALLEN, Martin Patrick , LI, Ling , MAPELLI, Claudio , POIRIER, Maude A. , SUN, Li-Qiang , ZHAO, Qian , MULL, Eric , GILLIS, Eric P. , SCOLA, Paul Michael
摘要: The present disclosure provides novel macrocyclic peptides which inhibit the PD-1/PD-L1 and PD-L1/CD80 protein/protein interaction, and thus are useful for the amelioration of various diseases, including cancer and infectious diseases.
-
-
-
-
-
-
-
-
-